Education
About Us
Working with TipRanks
Follow Us
Fate Therapeutics (FATE)
NASDAQ:FATE
FATE Stock Chart & Stats
$1.49
-$0.10(-5.71%)
At close: 4:00 PM EST
$1.49
-$0.10(-5.71%)
Day’s Range― - ―
52-Week Range$0.66 - $3.50
Previous CloseN/A
Volume630.90K
Average Volume (3M)2.83M
Market Cap
$171.84M
Enterprise Value-$8.74M
Total Cash (Recent Filing)$222.83M
Total Debt (Recent Filing)$81.33M
Price to Earnings (P/E)―
Beta2.59
Next Earnings
Oct 30, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding115,329,700
10 Day Avg. Volume2,488,182
30 Day Avg. Volume2,827,039
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.05
Enterprise Value/Revenue-1.03
Enterprise Value/Gross Profit-1.68
Enterprise Value/Ebitda0.05
Forecast
1Y Price Target
$4.42Price Target Upside196.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Financial StabilityFATE has extended its cash runway through early 2028, indicating financial stability to support ongoing operations.
Innovation In TreatmentFT836 and FT839 are advancing toward clinical entry without the need for conditioning chemotherapy, showcasing innovation in treatment approaches.
Trial And Recruitment PotentialFATE plans for a registrational trial of FT819 in lupus which could increase patient recruitment and future commercial prospects.
Bears Say
Durability Of Response ConcernsIt remains to be seen whether FT819 can achieve sufficient durability of response in lupus.
Uncertainty In Clinical PathIt remains unclear which therapeutic setting/dose will be taken forward given the diversity of reported data.
Workforce ReductionThe company also disclosed a 12% reduction in workforce which further extends cash runway through 2027.
Fate Therapeutics News
FATE FAQ
What was Fate Therapeutics’s price range in the past 12 months?
Fate Therapeutics lowest stock price was $0.66 and its highest was $3.50 in the past 12 months.
What is Fate Therapeutics’s market cap?
Fate Therapeutics’s market cap is $171.84M.
When is Fate Therapeutics’s upcoming earnings report date?
Fate Therapeutics’s upcoming earnings report date is Oct 30, 2025 which is today.
How were Fate Therapeutics’s earnings last quarter?
Currently, no data Available
Is Fate Therapeutics overvalued?
According to Wall Street analysts Fate Therapeutics’s price is currently Undervalued.
Does Fate Therapeutics pay dividends?
Fate Therapeutics does not currently pay dividends.
What is Fate Therapeutics’s EPS estimate?
Fate Therapeutics’s EPS estimate is -0.29.
How many shares outstanding does Fate Therapeutics have?
Fate Therapeutics has 115,329,700 shares outstanding.
What happened to Fate Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Fate Therapeutics?
Currently, no hedge funds are holding shares in FATE
Fate Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.42 (196.64% Upside)
$4.42 (196.64% Upside)
Blogger Sentiment
Bullish
FATE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $24.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-48.08%
12-Months-Change
Fundamentals
Return on Equity
-52.11%
Trailing 12-Months
Asset Growth
-29.72%
Trailing 12-Months
Company Description
Fate Therapeutics
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
FATE Stock 12 Month Forecast
Average Price Target
$4.42
▲(196.64% Upside)
Technical Analysis
Compugen
―
Oncolytics Biotech
―
Oncolytics Biotech
―
Cardiff Oncology
―
Nkarta
―
Shattuck Labs
―
Ownership Overview
12.95% Insiders
13.50% Mutual Funds
0.13% Other Institutional Investors
63.55% Public Companies and
Individual Investors